Volume 25

A Systematic Review of Adverse Influencing Factors in the Pharmaceutical Logistics Process Xingying Fan1,*, Duan Li1, Hanni Zhou1, Jiaqi Hu1 1, School of Medicine and Health Management, Guizhou Medical University, 561113, Guizhou, China. fanxingying777@126.com First author and corresponding author:  Xingying Fan, email: fanxingying777@126.com The Second Author:  Duan Li, email: 10958391@qq.com The Third Author: Hanni Zhou, email: 340370813@qq.com The Fourth Author: Jiaqi Hu, email: 411952179@qq.com Acknowledgement: Fund Project: 1: Science and Technology Foundation of Guizhou Provincial Health Commission, No. gzwkj2023-482 2: Research Center for Medical Economics and Management, Guizhou Medical University, No. GMUMEM2022-B06 3: Joint Fund Project of Department of Science and Technology of Guizhou Province (Qiankehe LH [2016]7377) Abstract Introduction: Pharmaceutical logistics is a complicated process that includes the storage, distribution, and transportation of pharmaceutical items, such as prescription medications, vaccinations, and medical equipment. Medicine is vital to society’s health. It is an essential component of the global healthcare sector since it guarantees that patients will get medical supplies and life-saving medications in a timely and safe manner. Objective:The purpose of this research is to give a complete overview of the factors influencing the pharmaceutical logistics process. Method: Following PRISMA principles, this review examines pharmaceutical supply chain management. This research is conducted in several databases from 2018 to 2022, including Web of Science, PubMed, Springer, Elsevier, and Scopus. This search was conducted using pharmaceutical logistics-related keywords. Result: The results indicate the affecting factors identified into various categories such as observation and management, storage and warehousing, distribution, physical and financial resources, human resources, and risk management. Conclusion:Itconcludes with suggestion for improving pharmaceutical logistics through increased risk management techniques, technology integration, and procedures, with the ultimate goal of guaranteeing the dependability and security of pharmaceutical supply chains. Keywords: Pharmaceutical, Logistics Process, Affecting Factors, Supply Chain, Systematic Review, PRISMA. 1. Introduction Timely and safe delivery of medicines from manufacturers to patients and health care providers is ensured through pharmacy management, a key link in health care Comprehensive analysis of adverse reactions affecting medicines management requires identifying, analyzing and integrating key information deCampos et al. [1]. These barriers include factors such as shipping, storage, regulatory compliance, and logistics for design problems Franco [2]. Because pharmaceutical products are highly sensitive to environmental factors such as moisture, heat and light, proper handling, storage and transportation are essential to ensure that pharmaceuticals will apply and any safeguards deviated from approved guidelines may affect drug quality and may harm patients in addition to future economic losses Suhandi and Chen[3]. In the pharmaceutical industry, it is important to meet several national and international requirements on, which is also heavily regulated. Compliance with these standards can result in recalls, delays, and financial penalties, affecting the entire supply chain Hansen et al. [4]. An important part of pharmaceutical manufacturing is a complex global supply chain, which often crosses multiple international borders in purchasing initial supply chains, pharmaceutical ingredients (APIs), and finished products Silva and Fegadolli[5].Pharmaceutical management must manage suppliers and customers to maintain quality and ensure supply, storage and warehousing, and other packaging safely for the sustainability of safe travel Although regulatory compliance is critical to maintaining global standards, proper distribution is essential to meet the demand. Returns and returns are handled through reverse logistics, and risk management is necessary to minimize disruption. Excellent customer service and support ensure stakeholder satisfaction, while technology integration improves follow-up and efficiency. Figure 1 illustrates the adapting to a rapidly changing environment requires stakeholders to collaborate and embrace challenges and new ideas. Figure 1: Challenges of pharmaceutical logistics process This challenge can lead to delays, theft, counterfeiting, and contamination, all of which can compromise patient safety. Logistics companies also face challenges related to insufficient resources in some industries, especially in developing countries, where inadequate roads, lack of cooling, and reliable vehicles are prohibited can interfere with timely and safe delivery of medicines Lee and Lee[6].Furthermore, the growing demand for biopharmaceuticals and customized pharmaceuticals requiring special handling and shipping poses new challenges for shippers Such pharmaceuticals this often requires harsh conditions and short delivery times, making conventional shipping methods inappropriate Goodarzian et al. [7].The emergence of technology advances included blockchain, the Internet of Things (IoT), and artificial intelligence (AI) offers prospects into improve traceability, transparency, with efficiency throughout the pharmaceutical supply chain. However, adoption of that equipment suffers from problems such as expensive installation costs, data security concerns and the need for industry-wide standardsSazvar et al. [8]. Ultimately, a systematic review of the negative effects of drug trafficking aims to inform stakeholders—manufacturers, shipping companies, law enforcement, and medical professionals—get a better understanding of the key barriers to effective and safe drug deliverySeale et al. [9]. Companies can identify and address these problems and work to develop reliable, efficient, patient-centered logistics systems, ensuring that medicines reach individuals in good condition regardless of operational or geographic barriers. To address the difficulties confronting the pharmaceutical industry, the study also highlights every importance about stakeholder engagement and continued investment in infrastructure, technology and regulation will be in the works Palit and Bhogal [10]. This study aims to investigate in detail the major factors influencing pharmaceutical logistics procedures. It looks for areas where it may be improved to guarantee the efficient, safe, and reliable distribution of pharmaceutical products. System in Overview The remaining part of this paper as divided as 4 sections such as the PRISMA is explained in Section 2. In section 3 discussed the result, and finally conclusion is covered by section 4. 2. Methodology The research model utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) method to locate with choose significant information in a practical and transparent manner. Regarding searching multiple databases using well-defined criteria, including specific inclusion and exclusion criteria, to identify studies relevant to the objectives of the study, this approach is enabled choosing the learning objectives properly is effective. 2.1 PRISMA diagram The PRISMAis a guideline used to enhance transparency and reporting quality in systematic reviews. In this study, it ensures a structured approach by clearly defining the search strategy, selection

Suwa Gu1, Zia Zhou2,* 1, Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215000, China. 2, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215000, China. Abstract  Background: A significant number of deaths and injuries are associated with the frequently late diagnosis of ovarian cancer. Psychological care is an essential component of palliative care. Effective palliative care for women undergoing chemotherapy for ovarian cancer recognizes the psychological impact of a serious illness and integrates psychological support to help these patients and their families cope. Aim: This research aims to evaluate how post-palliative care and standard oncologic care compare in terms of enhancing psychological support, overall well-being, pain relief, and quality of life in women undergoing chemotherapy for ovarian cancer. Methods: Participants will be randomly assigned to receive post-palliative care (Group B: n=75) and standard oncologic care (Group A: n=75). The outcomes will include patient satisfaction, healthcare utilization, psychological well-being, the impact of psychological support, pain relief, and quality of life offered through post-illiative care. Data will be collected at baseline and follow- up intervals of three, six, and twelve months. SPSS 26 version software has been employed for statistical analysis and will involve mixed-effects models to assess longitudinal changes, alongside independent t-tests, chi-square tests, and ANOVA for baseline comparisons. Results: Participants reported high symptom burden and poor quality of life at baseline. It is predicted that Group B will demonstrate significantly lower symptom burden, improved quality of life, enhanced psychological support, and higher patient satisfaction and psychological well-being compared to Group A. The results suggest that post-palliative care could lead to enhanced Patient Satisfaction-90%, Healthcare Utilization-20%, Psychological Well-Being-85%, Impact of Psychological Support-80%, Pain Relief-85%, and Quality of Life-80%. Conclusion: Integrating palliative care, particularly its psychological support components, into standard oncologic care for women undergoing chemotherapy for ovarian cancer could significantly enhance patient outcomes and overall well-being, warranting its routine consideration. Keywords: Ovarian Cancer, Palliative Care, Chemotherapy, Standard Oncologic Care, Quality of Life, Statistical Analysis, Psychological Well-Being, Psychological Care   1. Introduction  Ovarian cancer is considered a cancer that originates in the ovaries, which are the reproductive glands of females where the ovum and female major hormones such as estrogen and progesterone are produced [1]. Its early diagnosis is frequently difficult because its symptoms of enhancing the abdomen, pelvic pain, fatigue, etc. are depicted in Figure 1.  Figure 1: Ovarian Cancer Symptoms  Ovarian cancer is known to exist, and in women, it has spread to other areas of the abdomen or pelvis, making treatment more difficult [2]. Ovarian cancer is mainly classified into three types: epithelial tumors, germ cell tumors, and stromal tumors, which arise from varying cell types in the ovary [3]. Other factors that have been associated with the risks include the person’s age, the family history of the person, and unique genetic mutations such as the BRCA1 and BRCA2. To establish a diagnosis, imaging procedures such as ultrasound or CT scan, blood tests for specific markers such as CA-125, and biopsy procedures are usually utilized [4]. The treatment paradigm usually combines an operation to excise the mass of the cancer followed by systemic chemotherapy to eradicate any remaining tumor. In targeted therapy or immune therapy incorporated concerning ovarian cancer, there is no definite prevention but frequent doctor’s visits and knowledge improves the life span of patients [5]. There is no systematic screening for ovarian cancer; regular checkups and symptom vigilance would assist in its early detection. Cytotoxicity chemotherapy is an example of a therapeutic regimen used in cancer management; it involves taking antineoplastic medications, which are intended to kill tumor cells inside the body [6]. Chemotherapy targets rapidly proliferating and dividing cells, which is the hallmark of tumor cells, but it can also impact healthy, rapidly proliferating cells, including those in the skin, hair, bone marrow and Gastrointestinal (GI) tract. In the other forms of chemotherapy [7], ovarian cancer chemotherapy is always in the form of therapy aimed at the cancer cells in the ovary, as shown in Figure 2.  Figure 2: Chemotherapy for Ovarian Cancer It is most commonly administered after an operation to remove the cancer, which can also include any at-risk tissues (adjuvant chemotherapy) or to scale down the tumor before the operation (neoadjuvant chemotherapy). Ovarian cancer treatment typically includes chemotherapeutic drugs such as carboplatin and paclitaxel, which are intravenously administered through cyclic sessions with breaks in between to allow for recovery. Such treatment has possible side effects of nausea and vomiting, tiredness, baldness, etc [8]. Chemotherapy for ovarian cancer is possible due to the disease being manageable in the treatment of disease, while other strategies depend on the stage and type of cancer. Standard oncologic care includes more than chemotherapy and should understand the condition of a wide range of treatments such as surgery, targeted therapy, hormone therapy, immunotherapy, and others specific to the stage and nature of cancer [9]. In many ways to chemotherapy, where the focus is primarily on the cancer cells, standard oncologic care consists of a more extensive approach to treatment for the disease, including its eradication, and requires several specialists to coordinate and manage treatment of the patient. Palliative care for women suffering from conditions such as ovarian cancer is intended to relieve suffering by improving the quality of life through symptom control, pain relief, and psychological and mental support [10]. The present study aims to analyze the effects of post-palliative care and standard oncological treatment on the improvement of psychological support, overall well-being, pain relief, and quality of life for women with ovarian cancer during chemotherapy.  Contributions  The study organization assigns participants to a standard oncologic care group and a post- palliative care group, thereby facilitating reasonable comparisons of treatment.  Key factors such as patient satisfaction and health care utilization, psychological alleviation and pain control, and quality of life are measured, giving an overall perspective on the effects of post-palliative care and standard oncologic care.  Several follow-up data( at 3,6, and 12 months)